Citation Impact
Citing Papers
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis
2004
Infective Endocarditis
2005 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Complexities of Assessing the Disease Burden Attributable to Leishmaniasis
2008
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Single‐Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
2003
Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantumisolates from patients with visceral leishmaniasis
1999
Leishmaniasis
2018 Standout
Trial of oral miltefosine for visceral leishmaniasis
1998
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
2003
Ribosomes ofLeishmania are a target for the aminoglycosides
1995
Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
2006
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
Entrapment and release of quinoline derivatives using a hydrogel of a low molecular weight gelator
2004 StandoutNobel
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
2006
Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV Prevalence
2011
Liposomes, a promising strategy for clinical application of platinum derivatives
2013
Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin‐impregnated dog collars in southern Italy
2001
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
2007 Standout
A policy for leishmaniasis with respect to the prevention and control of drug resistance
2001
Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects
2000
Leishmaniasis in immunosuppressed individuals
2014
Post-kala-azar dermal leishmaniasis
2003
Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide
2014
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study
2000
In VivoInterference of Paromomycin with Mitochondrial Activity ofLeishmania
1997
Practical progress and new drugs for changing patterns of leishmaniasis
1993
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
2002 StandoutNature
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India Commentary: Some good news for treatment of visceral leishmaniasis in Bihar
1998
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs
2001
Leishmaniavaccines: progress and problems
2006
Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers
2012
Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature
2005
Effect of pegylation on pharmaceuticals
2003 Standout
A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries
2016
A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience
2004
ADVANCES IN MEDICAL AND ANTIBIOTIC MANAGEMENT OF INFECTIVE ENDOCARDITIS
1996
Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline
2003
Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica
1994
Liposomen
1997
Significantly Lower Anti-Leishmania IgG Responses in Sudanese versus Indian Visceral Leishmaniasis
2014
Nanocarriers for delivery of platinum anticancer drugs
2013
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
2002
Liposomal amphotericin B: clinical experience and perspectives
2005
Combination therapy for visceral leishmaniasis
2010
Chemotherapy in the Treatment and Control of Leishmaniasis
2006
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Preparation of Large Monodisperse Vesicles
2009 StandoutNobel
Leishmaniasis and poverty
2006
Pediatric visceral leishmaniasis in southern France
1998
PKDL and Other Dermal Lesions in HIV Co-infected Patients with Leishmaniasis: Review of Clinical Presentation in Relation to Immune Responses
2014
A Comparison of Miltefosine and Sodium Stibogluconate for Treatment of Visceral Leishmaniasis in an Ethiopian Population with High Prevalence of HIV Infection
2006
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
2012 StandoutNobel
Canine Leishmaniasis
2004
Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001)
2003
Lipsosomal Amphotericin B for Treatment of Cutaneous Leishmaniasis
2010
Neglected tropical diseases: survey and geometry of randomised evidence
2012
Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies
2000
Development and comparative evaluation of two antigen detection tests for Visceral Leishmaniasis
2015
Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region
2005
Treatment of leishmaniasis in HIV-positive patients
2003
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?
2014
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India
2015
Leishmaniasis Worldwide and Global Estimates of Its Incidence
2012 Standout
3. Visceral leishmaniasis
2001
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis
2000
Clinical aspects of visceral leishmaniasis in HIV infection
2012
Integrated Nanoparticle–Biomolecule Hybrid Systems: Synthesis, Properties, and Applications
2004 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Visceral Leishmaniasis in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients
2001
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
2003
Conflict and Kala‐Azar: Determinants of Adverse Outcomes of Kala‐Azar among Patients in Southern Sudan
2004
The pathogenesis ofLeishmania/HIV co-infection: cellular and immunological mechanisms
2003
Review: HIV infection and tropical parasitic diseases – deleterious interactions in both directions?
2002
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
2004
Evaluation of a mass distribution programme for fine‐mesh impregnated bednets against visceral leishmaniasis in eastern Sudan
2007
Liposomes in Drug Delivery
1993
The immunology of post-kala-azar dermal leishmaniasis (PKDL)
2016
Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge
2010
A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
2000
Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisome®)
2000
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
2002
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B
1999
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice
2009
U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis
1999
Interleukin‐12 Regulates the Response to Chemotherapy in Experimental Visceral Leishmaniasis
2000
Designing dendrimers for biological applications
2005 Standout
Organic Switches for Surfaces and Devices
2012 StandoutNobel
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Leishmaniasis: drugs in the clinic, resistance and new developments
2004
Unseen Kala‐azar deaths in south Sudan (1999–2002)
2006
Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent
2007
Leishmania Induces Survival, Proliferation and Elevated Cellular dNTP Levels in Human Monocytes Promoting Acceleration of HIV Co-Infection
2012
pH-Responsive mechanised nanoparticles gated by semirotaxanes
2009 StandoutNobel
Control of Neglected Tropical Diseases
2007 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Drug discovery and development for neglected parasitic diseases
2006
Liposomal amphotericin B as a treatment for human leishmaniasis
2012
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
2002
Leishmaniasis
1999 Standout
Two Doses of a Lipid Formulation of Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis
2003
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trialCommentary: cost and resistance remain issues
2001
LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014
2013
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA
2005
COMPARISON OF GENERIC TO BRANDED PENTAVALENT ANTIMONY FOR TREATMENT OF NEW WORLD CUTANEOUS LEISHMANIASIS
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Leishmania infantum : Lack of Parasite Resistance to Amphotericin B in a Clinically Resistant Visceral Leishmaniasis
1998
Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma
2005
Visceral Leishmaniasis Treatment, Italy
2003
Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study
2015
Leishmania and human immunodeficiency virus coinfection: the first 10 years
1997
Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature
2016
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Treatment options for visceral leishmaniasis
2006
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Shrink-Wrap Vesicles
2005 StandoutNobel
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
2005
Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis
2001
Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances Antiparasitic Immunity
2010 StandoutNobel
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
2023 StandoutNobel
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Current scenario of drug development for leishmaniasis.
2006
Advances in leishmaniasis
2005 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
EVALUATION OF A NEW RECOMBINANT K39 RAPID DIAGNOSTIC TEST FOR SUDANESE VISCERAL LEISHMANIASIS
2006
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation
2003
Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years
1997
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine
1993
Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
2001
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
The Illusion of Sustainability
2007 StandoutNobel
Activities of Hexadecylphosphocholine (Miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) against Leishmania donovani in Immunodeficient scid Mice
2001
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Visceral Lieshmaniasis and HIV co-infection in patients admitted to Gondar University Hospital, Northwest Ethiopia
2007
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
2008
Diagnosis and treatment of Indian visceral leishmaniasis.
2003
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs
2005
Mechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes
1998
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
2016
Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex
1998
UTILITY OF LYMPH NODE ASPIRATION IN THE DIAGNOSIS OF VISCERAL LEISHMANIASIS IN SUDAN
2007
Antimony Toxicity
2010
Field Evaluation of rK39 Test and Direct Agglutination Test for Diagnosis of Visceral Leishmaniasis in a Population with High Prevalence of Human Immunodeficiency Virus in Ethiopia
2009
Drug Resistance in Leishmaniasis
2006 Standout
Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field
2016
Generation of Anti-trypanosomal Agents through Concise Synthesis and Structural Diversification of Sesquiterpene Analogues
2011 StandoutNobel
Works of R.N. Davidson being referenced
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
1998
Miltefosine to treat cutaneous leishmaniasis caused byLeishmania tropica
2009
Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis
1996
Epidemic Visceral Leishmaniasis in Sudan: A Randomized Trial of Aminosidine plus Sodium Stibogluconate versus Sodium Stibogluconate Alone
1993
Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989–2003
2003
Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis
1993
Phase�I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum�II entrapped in multilamellar liposome vesicles
2003
Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
2001
Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum
1995
Liposomal amphotericin B in the treatment of visceral leishmaniasis
1991
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis
2005
Group G streptococcal endocarditis: two case reports, a review of the literature and recommendations for treatment
1988
Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom
1992
Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
1996
Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, northeastern Kenya, and south-eastern Ethiopia in 2000–2001
2003
Liposomal amphotericin B in drug-resistant visceral leishmaniasis
1991
Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions
1995
Practical Guide for the Treatment of Leishmaniasis
1998
Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)
1996
Concordant HIV Infection and Visceral Leishmaniasis in Ethiopia: The Influence of Antiretroviral Treatment and Other Factors on Outcome
2008
Activity of Liposomal Amphotericin B (AmBisome) AgainstLeishmania infantumand Tissue Distribution in Mice
1993
Visceral leishmaniasis in clinical practice
1999
Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy
2006
Treatment of Kala-Azar in Southern Sudan using a 17-Day Regimen of Sodium Stibogluconate Combined with Paromomycin: A Retrospective Comparison with 30-Day Sodium Stibogluconate Monotherapy
2007
Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
2013
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
1994